ABL1 F317L

CI-VAR-00001105Explore in graph →NP_005148.2:p.Phe317LeuNM_005157.5:c.951C>GClinVar 376094 CIViC 1028 rs1057519773 rs121913451

Curated evidence

Evidence by cancer (26 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–26 of 26 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive24
BCR::ABL1 Fusion AND ABL1 F317L	Axitinib	Predictive	D	Supports Resistance	2	accepted	EID4390 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with t… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 F317L	Axitinib	Predictive	D	Supports Resistance	2	accepted	EID4391 In an in vitro study, a pro-B Ba/F3 cell line expressing F317L mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated resistance to axitinib treatment (IC50: 1170nM)… (full text at CIViC) PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm2
BCR::ABL1 Fusion AND ABL1 F317L	Dasatinib + ImatinibSubstitutes	Predictive	D	Supports Resistance	3	accepted	EID7839 In an in vitro study, a Ba/F3 cell line stably expressing the F317L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and dasatinib treatment (IC50… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 F317L	Bafetinib + NilotinibSubstitutes	Predictive	D	Does Not Support Resistance	3	accepted	EID2677 In an in vitro study, a Ba/F3 cell line stably expressing the F317L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib treat… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic